Literature DB >> 23093460

Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly.

P Anagnostis1, Z A Efstathiadou, S Gougoura, S A Polyzos, E Karathanasi, P Dritsa, M Kita, G N Koukoulis.   

Abstract

Acromegaly is characterized by high cardiovascular morbidity and mortality. Oxidative stress and endothelial dysfunction are underlying mechanisms of atherosclerosis.The aim of this study was to evaluate the blood redox status and endothelial function by means of nitric oxide (NO) levels in patients with acromegaly. Total antioxidant capacity (TAC), catalase activity and glutathione concentration (GSH), as measures of antioxidative capacity, total oxidized glutathione (GSSG) and thiobarbituric acid reactive substances (TBARS), as indices of oxidative stress, and NO levels were assessed in 15 patients with acromegaly (age 55.4±10.5 years; 6 males) and 15 age- and sex-matched controls (age 58.4±8.1 years; 7 males). Active disease was present in 12 patients: 11 on current pharmacotherapy and 1 newly diagnosed. Three acromegalics were in remission after successful treatment. Acromegalics as compared with controls had significantly lower levels of catalase activity (8.2±5.8 vs. 51.3±29.1 mmol/ml/min, p<0.001), GSH (0.97±0.54 vs. 1.41±0.35 mmol/l, p=0.006), GSSG (0.27±0.19 vs. 2.04±1.32 mmol/l, p=0.002) and NO levels (6.0±3.1 vs. 43.0±29.8 mmol/l, p<0.001), but higher TBARS (16.3±8.9 vs. 10.1±10.8, nmol/ml, p=0.019). After adjustment for confounders, differences in catalase activity, NO levels and TBARS remained significant (p=0.004, p<0.001 and p=0.025, respectively). No association between IGF-I/GH and oxidative stress markers was noticed, except for a positive correlation between nadir GH and GSSG (r²=0.563, p=0.036). Acromegaly is associated with increased levels of oxidative stress coupled by diminished antioxidant capacity and endothelial dysfunction indicated by the presence of decreased NO levels. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093460     DOI: 10.1055/s-0032-1323765

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  11 in total

1.  Insight into cardiovascular risk factors in patients with acromegaly.

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

2.  Short-term, supra-physiological rhGH administration induces transient DNA damage in peripheral lymphocytes of healthy women.

Authors:  C Fantini; P Sgrò; M Pittaluga; A de Perini; I Dimauro; A Sartorio; D Caporossi; L Di Luigi
Journal:  J Endocrinol Invest       Date:  2017-02-16       Impact factor: 4.256

3.  Arterial properties in acromegaly: relation to disease activity and associated cardiovascular risk factors.

Authors:  Marianna Yaron; Elena Izkhakov; Jessica Sack; Ibrahim Azzam; Etty Osher; Karen Tordjman; Naftali Stern; Yona Greenman
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

4.  Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.

Authors:  Dilek Arpaci; Sevim Karakas Celik; Murat Can; Esra Ermiş; Fatih Kuzu; Furuzan Kokturk; Ayse Ceylan Hamamcioglu; Ahmet Dursun; Taner Bayraktaroglu
Journal:  Redox Rep       Date:  2016-02-15       Impact factor: 4.412

Review 5.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Authors:  Cigdem Ozkan; Alev Eroglu Altinova; Ethem Turgay Cerit; Cagri Yayla; Asife Sahinarslan; Duygu Sahin; Aylin Sepici Dincel; Fusun Balos Toruner; Mujde Akturk; Metin Arslan
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

7.  High chitotriosidase and AGE levels in acromegaly: a case-control study.

Authors:  Hatice Ozisik; Banu Sarer Yurekli; Aslı Suner; Oznur Copur; Eser Yıldırım Sozmen; Suha Sureyya Ozbek; Ahmet Kasım Karabulut; Ilgın Yıldırım Simsir; Mehmet Erdogan; Sevki Cetinkalp; Fusun Saygili
Journal:  Hormones (Athens)       Date:  2022-10-15       Impact factor: 3.419

8.  Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?

Authors:  Panagiotis Anagnostis; Zoe A Efstathiadou; Maria Charizopoulou; Despina Selalmatzidou; Eleni Karathanasi; Maria Poulasouchidou; Marina Kita
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

9.  Erectile Dysfunction Is Associated With Excessive Growth Hormone Levels in Male Patients With Acromegaly.

Authors:  Zhengyuan Chen; Xiaoqing Shao; Min He; Ming Shen; Wei Gong; Meng Wang; Yichao Zhang; Wenjuan Liu; Zengyi Ma; Zhao Ye; Yongning Lu; Nianqin Yang; Shanwen Chen; Lydia Hu; Yiming Li; Yongfei Wang; Yao Zhao; Zhaoyun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-04       Impact factor: 5.555

Review 10.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.